• Explore /
  • Poster
  • / Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.

Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.

Abstract Poster

Authors

null

Vicky Makker

Memorial Sloan-Kettering Cancer Center, New York, NY

Vicky Makker , Fernando O. Recio , Ling Ma , Ursula Matulonis , Jennifer O'Hara Lauchle , Hema Parmar , Houston Gilbert , Yulei Wang , Hartmut Koeppen , Jill M Spoerke , Mark Lackner , Carol Aghajanian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Clinical Trial Registration Number

NCT01455493

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)

DOI

10.1200/jco.2014.32.15_suppl.5513

Abstract #

5513

Poster Bd #

2

Abstract Disclosures

Similar Posters

First Author: Neesha C. Dhani

First Author: Andrea P. Myers

First Author: B.J. Rimel

First Author: Mario Javier Pineda